DAVIO Trial Updates

Ashkan M. Abbey, MD

Show Description +

Ashkan M. Abbey, MD, shares safety and preliminary efficacy data from the phase 1 trial of EYP-1901 (EyePoint) for the treatment of wet AMD.

Posted: 5/15/2023

Keywords:

EyePoint Pharmaceuticals

•

Wet AMD

•

retina-meeting-recap

•

Clinical Trials

Up Next

Name: DAVIO Trial Updates
Uploaded: 2023-05-15T17:11:55+00:00
Description: Ashkan M. Abbey, MD, shares safety and preliminary efficacy data from the phase 1 trial of EYP-1901 (EyePoint) for the treatment of wet AMD.

The Latest From LIGHTSITE III

Marion R. Munk, MD, PhD

A Look at Visual Outcomes in GATHER2

Carl Danzig, MD

New Phase 1 Data for OTX-TKI

Andrew Moshfeghi, MD

Reducing AMD Risk with Metformin

Neal Peachey, PhD

The Value of Multimodal Imaging in Diabetic Retinopathy

Stela Vujosevic, MD, PhD, FARVO, FEBO

The Risk of iRORA Revealed

Hanna Choi, BS

Tackling the Diabetic Retinopathy "Pandemic"

Tien Yin Wong, MBBS, MMED (Ophth), MPH, PhD

DAVIO Trial Updates

Ashkan M. Abbey, MD

Back to All Videos

DAVIO Trial Updates

Ashkan M. Abbey, MD

Ashkan M. Abbey, MD, shares safety and preliminary efficacy data from the phase 1 trial of EYP-1901 (EyePoint) for the treatment of wet AMD.

Posted: 5/15/2023

Keywords:

EyePoint Pharmaceuticals

•

Wet AMD

•

retina-meeting-recap

•

Clinical Trials

Please log in to leave a comment.

Meeting Coverage:

Association for Research in Vision & Ophthalmology

DAVIO Trial Updates

Up Next

DAVIO Trial Updates

More From ARVO: 2023 Coverage